title: Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.
abstract: We show herein that human DNA topoisomerase II beta is functional in yeast. It can complement a yeast temperature-sensitive mutation in topoisomerase II. The effect on human topoisomerase II beta of a number of topoisomerase II inhibitors was analysed in a yeast in vivo system and compared with that of human topoisomerase II alpha and wild-type yeast topoisomerase II. A drug permeable yeast strain (JN394 top2-4) was used to analyse the in vivo effects of known anti-topoisomerase II agents on human topoisomerase II beta transformants. A parallel analysis on human topoisomerase II alpha transformants provides the first in vivo analysis of the responses of yeast bearing the individual isoforms to these drugs. The strain was analysed at 35 degrees C, a non-permissive temperature at which only plasmid-borne topoisomerase II is active. A shuttle vector with either human topoisomerase II beta, human topoisomerase II alpha or yeast topoisomerase II under the control of a GAL1 promoter was used. The key findings were that amsacrine produced comparable levels of cell killing with both alpha and beta, whilst etoposide, doxorubicin and mitoxantrone produced higher degrees of cell killing with alpha than with beta or yeast topoisomerase II. Merbarone had the greatest effect on the yeast strain bearing plasmid-borne yeast topoisomerase II. Suramin, quercetin and genistein showed little cell killing in this system. This yeast in vivo system provides a powerful way to analyse the effects of anti-topoisomerase II agents on transformants bearing the individual human isoforms. This system also provides a means of analysing putative drug-resistance mutations in human topoisomerase II beta or to select for drug-resistance mutations in human topoisomerase II beta.
authors.affiliation: Department of Biochemistry and Genetics, Medical School, University of Newcastle-upon-Tyne, U.K.
authors.forename: E L
authors.initials: EL
authors.lastname: Meczes
authors.forename: K L
authors.initials: KL
authors.lastname: Marsh
authors.forename: L M
authors.initials: LM
authors.lastname: Fisher
authors.forename: M P
authors.initials: MP
authors.lastname: Rogers
authors.forename: C A
authors.initials: CA
authors.lastname: Austin
mesh_terms: D000677:Amsacrine / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D005816:Genetic Complementation Test; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D012441:Saccharomyces cerevisiae / Q000201:enzymology*; D013696:Temperature; D059005:Topoisomerase II Inhibitors; D014170:Transformation, Genetic
chemical_list: D007527:Isoenzymes; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D004250:DNA Topoisomerases, Type II